Original Query: ALL
Previous Study | Return to List | Next Study

Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02247622
Recruitment Status : Unknown
Verified September 2014 by ido laish, Meir Medical Center.
Recruitment status was:  Recruiting
First Posted : September 25, 2014
Last Update Posted : September 25, 2014
Information provided by (Responsible Party):
ido laish, Meir Medical Center

Brief Summary:
PSC is a chronic cholestatic disorder. The investigators intend to study some telomere parameters and telomere length in order to predict a premalignant state.

Condition or disease
Primary Sclerosing Cholangitis Inflammatory Bowel Disease

Detailed Description:
Primary sclerosing cholangitis (PSC) and colitis are chronic inflammatory disorders with malignant potential. Telomerase is an enzyme complex that lengthens telomeres and has enhanced expression in numerous malignancies. In this study, we evaluated the telomerase gene copy number, telomere length, cells in senescence, aneuploidy and additional parameters of telomere dysfunction from peripheral blood lymphocytes of patients.

Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Primary Sclerosing Cholangitis Telomere Length
Study Start Date : February 2012
Estimated Primary Completion Date : September 2014
Estimated Study Completion Date : September 2014

Healthy control
patients with inflammatory bowel disease, study group
patients with primary sclerosing cholangitis, study group

Primary Outcome Measures :
  1. Telomere length [ Time Frame: 1.5 years ]

Secondary Outcome Measures :
  1. number of cells with increased telomerase RNA component (TERC) expression [ Time Frame: 1.5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients with primary sclerosing cholangitis and inflammatory bowel disease

Inclusion Criteria:

  • informed consent
  • documented PSC and inflammatory bowel disease

Exclusion Criteria:

  • under 18 years, above 80 y
  • known active malignancy
  • decompensated cirrhosis
  • patients who cannot sign informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02247622

Contact: Ido Laish, MD +972-549477261

Meir Medical Center Recruiting
Kfar Saba, Israel
Contact: Ido Laish, MD   
Principal Investigator: Ido Laish, Md         
Sponsors and Collaborators
Meir Medical Center

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: ido laish, Md., Meir Medical Center Identifier: NCT02247622     History of Changes
Other Study ID Numbers: 1.1
First Posted: September 25, 2014    Key Record Dates
Last Update Posted: September 25, 2014
Last Verified: September 2014

Keywords provided by ido laish, Meir Medical Center:

Additional relevant MeSH terms:
Inflammatory Bowel Diseases
Cholangitis, Sclerosing
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Bile Duct Diseases
Biliary Tract Diseases